(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 December 2011 (01.12.2011)

PCT

(10) International Publication Number
WO 2011/147810 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 9/00* (2006.01)
A61K 31/437 (2006.01) *A61P 15/00* (2006.01)

(21) International Application Number:
PCT/EP2011/058433

(22) International Filing Date:
24 May 2011 (24.05.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10 2010 021 637.2 26 May 2010 (26.05.2010) DE
10170413.8 22 July 2010 (22.07.2010) EP

(71) Applicant *(for all designated States except US)*: **BAYER PHARMA AKTIENGESELLSCHAFT** [DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HIRTH-DIETRICH, Claudia** [DE/DE]; Stockmannsmühle 127, 42115 Wuppertal (DE). **SANDNER, Peter** [DE/DE]; Julius-Lucas-Weg 59, 42113 Wuppertal (DE). **STASCH, Johannes-Peter** [DE/DE]; Alfred-Nobel-Str.109, 42651 Solingen (DE). **KNORR, Andreas** [DE/DE]; Trillser Graben 10, 40699 Erkrath (DE). **VON DEGENFELD, Georges** [FR/DE]; Friedrich-Weskott-Str. 10, 51373 Leverkusen (DE). **HAHN, Michael** [DE/DE]; Rietherbach 42D, 40764 Langenfeld (DE). **FOLLMANN, Markus** [DE/DE]; Ringstr. 61, 42489 Wülfrath (DE).

(74) Common Representative: **BAYER PHARMA AKTIENGESELLSCHAFT**; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2011/147810 A1

(54) **Title**: THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc).

(57) **Abstract**: The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.

The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc).

The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.

Background of the invention

Systemic Sclerosis

The pathogenesis of Systemic Sclerosis (SSc) is still unclear and remains elusive. However, scleroderma is a non-inherited, noninfectious disease and thought to be an autoimmune disease. SSc has a broad variety of symptoms triggered by excessive deposition of extracellular matrix in the dermis resulting in skin fibrosis. In later stages SSc is characterized by progressive tissue fibrosis affecting other internal organs as the gut, the lung or the kidneys. Therefore scleroderma is the hallmark of the disease comprising also e.g. lung fibrosis, renal fibrosis, fibrosis of the heart, the gut or the blood vessels. It is suggested that inflammation, autoimmune disorders or vascular damage activates fibroblasts. Fibroproliferation is accompanied by excessive extracellular matrix production, dominated by Collagen type I resulting in progressive tissue fibrosis which can cause end organ failure and lead to high morbidity and mortality in patients with end-stage SSc (Harris et al. 2005 - Kelley´s Textbook of Rhematology 7th edition. Elsevier Saunders, Philadelphia PA).

There is still no causative treatment for Systemic Sclerosis (SSc) available and the current therapy is based on suppression of the immune system via corticosteroids, cyclophosphamide, methotrexate. More recently kinase inhibitors are under investigation as immunosuppressant and antifibrotic agents in SSc, but tolerability is limited in SSc patients (Khanna and Denton 2010 - Best. Pract. Res. Clin. Rheumatol. 24:387-400, Ong and Denton 2010 - Curr. Opin. Rheumatol. 22:264-272, Spiera 2011 - Ann. Rheum. Dis. Epub Mar 2011). These therapies either used as stand alone treatment or combined are of limited efficacy and exhibited considerable side effects. Therefore alternative treatment options in SSc which are efficacious and safe are urgently needed.


Antifibrotic effects of cGMP:

The cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), were discovered decades ago and represent one of the most important second messenger pathway within cells. It is well established that the regulation of intra-cellular cGMP pools have substantial impact on physiology, and pathophysiology and is one basic principle of pharmacological intervention (Evgenov et al. 2006 - Nat. Rev. Drug. Discov.

5(9):755-768). Besides the treatment of cardiovascular, lung or CNS-disorders there is ample evidence that an increase in cGMP is a very effective treatment option for urological disorders as well (Sandner et al. 2009 – Handbook Exper. Pharmacol. 191:507-531). PDE5 inhibitors are the gold-standard for the treatment of erectile dysfunction (ED) but it was shown that PDE5 inhibitors could be useful for the treatment of symptomatic BPH which is characterized by Overactive Bladder (OAB) and Lower Urinary Tract Symptoms (LUTS) (Porst et al. 2008 - Curr. Urol. Rep. 9:295-301; .McVary et al. 2007 - J. Urol. 177:1071-1077, J Urol. 177:1401-1407, Kaplan and Gonzalez. 2007 - Rev. Urol. 9:73-77). The antifibrotic effects of Vardenafil, sGC stimulators and sGC activators is not understood yet. There are some descriptions about antifibrotic effects of Nitric-Oxide which are presumably mediated by cGMP in other organs and PDE5 inhibitors or guanylate cyclase stimulators have shown efficacy in penile fibrosis (Peyronie´s disease) (Ferrini et al. 2006 - B. J. Urol. 97:625-633) and liver fibrosis (Knorr et al. 2008 - Arzneimittelforschung 58:71-80) respectively.

It is not known if the NO/cGMP system is involved in SSc and if cGMP increase provides a treatment option for this disease. We hypothetized that – independent from endogenous NO/cGMP production – sGC stimulators and activators might be an effective treatment option for Systemic Sclerosis (SSc).

We therefore investigated sGC stimulators and sGC activators, i.e. example 27 according to compound of the formula



(27)

and combinations with PDE5 inhibitors thereof in vitro and in vivo in animal models for SSc. The in vivo experiments are including studies in bleomycin-induced skin and lung fibrosis in mice and

studies on skin fibrosis in TSK-mice. In addition, the dose range tested on antifibrotic potential was also analyzed in mice with telemetric implants for blood-pressure and heart rate analysis.

We found in vivo in our animal models that:

- sGC stimulators or sGC activators, i.e. example 27, example 3, example 6, significantly reduced dermal thickness, hydroxyproline content of the skin and the number of dermal myofibroblasts in bleomycin-induced SSc in mice when administered in a preventive dose-regimen. (Example A: Table 1, Table 2). These data suggest an antifibrotic effect in Systemic Sclerosis when these compounds are given preventively.

- sGC stimulators or sGC activators, i.e. example 27 significantly reduced dermal thickness, hydroxyproline content of the skin and the number of dermal myofibroblasts in bleomycin-induced SSc in mice when administered in a therapeutic dose-regimen after established fibrosis. (Example B: Table 3). These data suggest an antifibrotic effect and regression of established fibrosis in Systemic Sclerosis when the compounds are given therapeutically.

- sGC stimulators or sGC activators, i.e. example 27 significantly reduced dermal thickness, hydroxyproline content of the skin and the number of dermal myofibroblasts in TSK mice. Since TSK mice already exhibited established fibrosis before start of the treatment example 27 caused fibrosis-regression (Example C: Table 4). These data suggest an antifibrotic effect and regression of established fibrosis in Systemic Sclerosis when the compounds are given therapeutically.

- sGC stimulators of sGC activators, i.e. example 27, example 3, example 4, example 6 were investigated in conscious mice with telemetric implants and blood pressure and heart rate was monitored (Example D). Example 27, example 3, example 4, example 7 did not or only moderately, change the heamodynamic profile of the mice in dosages with antifibrotic properties (Example D: Figures 1, 2A, 2B, 3A, 3B, 4A, 4B). These data suggest a direct antifibrotic mode of action of sGC stimulators and sGC activators independent of blood pressure reduction by these compounds.

- sGC stimulators or sGC activators, i.e. example 27, alone and in combination with PDE5 inhibitors (i.e. Vardenafil) blocked TGF-induced collagen gene expression in vitro in human dermal fibroblasts(Example E). These data suggest a direct antifibrotic effect on the level of collagen production

Thus, we found completely unexpected and for the first time that sGC stimulators or sGC activators i.e. example 27, prevent fibrosis and regress established fibrosis in different animal models of

inflammatory and non-inflammatory SSc including bleomycin-induced fibrosis models and the TSK-mouse model.

In addition there was no significant effect seen on systemic blood pressure which for the first time shows that these sGC stimulators have direct antifibrotic properties in SSc independent from blood pressure reduction.

Moreover sGC stimulators and sGC activators could block TGF-beta induce collagen synthesis implying a broad antifibrotic effect in other fibrotic disorders beyond SSc.

Taken together this data indicate for the first time that sGC stimulators and sGC activators, i.e. Example 27, example 3, example 4, example 6 could represent a future treatment option for SSc.

Disclosure of the invention

Fibrotic disorders addressed by therapeutic agents of the invention which in particular and with substantial advantage can be treated by the above mentioned sGC stimulators or sGC activators alone or in combination with PDE5 inhibitors comprise but are not limited to Systemic Sclerosis (SSc), Systemic Sclerosis (SSc) concomitant fibrosis and fibrotic diseases.

Systemic Sclerosis (SSc) refers to but is not limited to diffuse Systemic Sclerosis (dSSc), limited Systemic Sclerosis (lSSc), overlap type of Systemic Sclerosis, undifferentiated type of Systemic Sclerosis, Systemic Sclerosis sine scleroderma, skin fibrosis, scleroderma, nephrogenic fibrosing dermopathy (NFD), nephrogenic systemic fibrosis (NSF), keloid formation.

SSc concomitant fibrosis refers to fibrosis of internal organs, comprising but not limited to the gut, the lung, the kidney and the blood vessels.

Fibrotic diseases comprises but are not limited to a condition in which collagen excess - independent of the etiology i.e. autoimmune disorders, radiation therapy, intoxications, diabetes, surgery – lead to fibrosis of the skin, gut, liver, lung, heart, bladder, prostate, blood vessels or any other localized or generalized fibrotic condition in tissues.

A preferred embodiment of the invention is compounds according to formulae (1)-(27) for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs, as shown below:


- 2-[1-(2-Fluorbenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-(4-morpholinyl)-4,6-pyrimidine-diamine (1), disclosed as example 16 in WO 00/06569,
- 2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-(4-pyridinyl)-4-pyrimidineamine (2), disclosed as example 1 in WO 02/42301,
- Methyl-4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-pyrimidinyl-(methyl)carbamate (3), disclosed as example 8 in WO 03/095451,
- Methyl-4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-pyrimidinyl-carbamate (4), disclosed as example 5 in WO 03/095451
- 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]amino}methyl) carboxylic acid (5), disclosed as example 8a in WO 01/019780,
- Methyl-{4,6-diamino-2-[5-fluoro-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridine-3-

yl]pyrimidine-5-yl}carbamate (6),


- Methyl-{4,6-diamino-2-[5-fluoro-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidine-5-yl}methylcarbamate (7),
- Methyl-{4,6-diamino-2-[5-fluoro-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidine-5-yl}(2,2,2-trifluorethyl)carbamate (8),
- 5-Chloro-2-(5-chlorothiophene-2-sulfonylamino-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamid as sodium salt (9), disclosed in WO00/02851,
- 2-(4-Chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide (10), disclosed in WO00/02851,
- 1-{6-[5-Chloro-2-({4-trans-4-}trifluoromethyl)cyclohexyl]benzyl}oxy)phenyl]pyridine-2-yl}-5-(trifluoromethyl)-1H-pyrazol-4-carboxylic acid (11), disclosed in WO 2009/032249,
- 1-[6-(2-(2-Methyl-4-(4-trifluoromethoxyphenyl)benzyloxy)-phenyl)pyridine-2-yl]-5-trifluoromethyl-pyrazol-4-carboxylic acid (12), disclosed in WO 2009/071504,
- 1[6-(3,4-dichlorophenyl)-2-pyridinyl-5-(trifluoromethyl)-1H-pyrazole-4-caboxylic acid (13), disclosed in WO 2009/068652,
- 1-({2-[3-Chlor-5-(trifluoromethyl)phenyl]-5-methyl-1,3-thiazole-4-yl}methyl)-1H-pyrazole-4-carboxylic acid (14), 4-({2-[3-(Trifluoromethyl)phenyl]-1,3-thiazole-4-yl}methyl)benzoic acid (15) and 1-({2-[2-Fluoro-3-(trifluoromethyl)phenyl]-5-methyl-1,3-thiazole-4-yl}methyl)-1H-pyrazole-4-carboxylic acid (16) disclosed in WO 2009/123316,
- 4-Amino-2-[5-chloro-3(3,3,3-trifluororpropyl)-1H-indazol-1yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidine-6-one (17), 4-Amino-2[5-chloro-3-(2,3,6-trifluorbenzyle)-1H-indazol-1yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidine-6-one (18), 4-Amino-5,5-dimethyl-2-[3-(2,3,6-trifluorbenzyle)1H-thieno[3,4-c]pyrazol-1-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidine-6-one (19), 4-Amino-5,5-dimethyl-2-[3-(2,3,6-trifluorbenzyle)-1H-thieno[2,3-d]pyrazole-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidine-6-one (20), 4-Amino-5,5-dimethyl-2-[7-(2,3,6-trifluorobenzyle)imidazo[1,5-b]pyridazine-5-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidine-6-one (21), 4-Amino-2-[6-chloro-3-(2,3,6-trifluorobenzyle)imidazo[1,5-a]pyridine-1-yl]]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidine-6-one (22), 4-Amino-2-[6-fluoro-3-(2,3,6-trifluorobenzyle)imidazo[1,5-a]pyridine-1-yl]]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidine-6-one (23), 4-Amino-2-[6-fluoro-3-(2,3,6-trifluorobenzyl)6-fluoroimidazo[1,5-a]pyridine-1-yl]-5,5-dimethyl-5,7-

dihydro-6H-pyrrolo[2,3-d]pyrimidine-6-one (24), 4-Amino-5,5-dimethyl-2-[3-(2,4,6-trifluorobenzyle)imidazo[1,5-a]pyridine-1-yl]]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidine-6-one (25), 4-Amino-2-[3-(2-cyclopentylethyl)imidazo[1,5-a]pyridine-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidine-6-one (26), disclosed in WO 2010/065275,


- 3-(4-Amino-5-cyclopropylpyrimidin-2-yl)-1-(2-fluorobenzyl)-1*H*-pyrazolo[3,4-*b*]pyridine (27) known as BAY 41-2272 disclosed as example 1 in WO 00/06568.




(1)




(2)




(3)




(4)




(5)




(6)




(7)




(8)




(9)




(10)




(11)




(12)




(13)




(14)




(15)




(16)




(17)




(18)




(19)




(20)




(21)




(22)




(23)




(24)



(25)



(26)



(27).

Compounds according to formulae (1), (2), (3), (4), (6)-(8) and (17)-(27) are known as sGC stimulators. Preferred are compounds according to formulae (1), (2), (3), (4), (6), (7) and (27). Especially preferred are compounds according to formulae (3), (4), (6) und (7).

Compounds according to formulae (5) und (9)-(16) are known as sGC activators. Preferred is the compound according to formula (5).

A further embodiment of the invention is the combination of stimulators and/or activators of the soluble guanylate cyclase with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as Systemic Sclerosis, scleroderma, and the concomitant fibrosis of internal organs. The following PDE 5 inhibitors are preferred for the combination with sGC stimulators and/or activators:

Tadalafil ((6R,12aR) -2,3,6,7,12,12a – Hexahydro – 2 – methyl – 6 - (3,4-methylene -dioxyphenyl) pyrazino(1',2':1,6) pyrido(3,4-b)indole-1,4-dione), *Vardenafil* (2-(2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3H-imidazo (5,1-f) (1,2,4)triazin-4-one), *Sildenafil* (3-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonyl-phenyl]- 7- methy l- 9- propy l-2,4,7,8- tetrazabicyclo [4.3.0]nona -3,8,10-trien-5-one), *Udenafil* 5-[2-propyloxy-5-(1-methyl-2-pyrrolidinylethylamidosulfonyl)phenyl]-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one, *Dasantafil* 7-(3-Bromo-4-methoxybenzyl)-1-ethyl-8-[[(1,2)-2-hydroxycyclopentyl]amino]-3-(2-hydroxyethyl)-3,7-dihydro-1-purine-2,6-dione, *Avanafil* 4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide, Mirodenafil, Lodenafil, UK 369.003, UK 371.800, *SLx 2101* of Surface Logix, *LAS 34179*Triazolo[1,2-]xanthine,6-methyl-4-propyl-2-[2-propoxy-5-(4-methylpiperazino)sulfonyl]phenyl or salts, hydrates or hydrates of the salts.

Especially preferred are combinations of compounds according to formulae (1), (2), (3), (4), (6), (7), (27) and /or (5) with vardenafil and/or sildenafil

Especially preferred are combinations of compounds according to formulae (3), (4), (6), (7) and /or (5) with vardenafil and/or sildenafil for use in the prevention and/or treatment of Systemic Sclerosis (SSc).

Especially preferred are compounds according to formulae 3, 4, 6, and/or 7 for use in the prevention and/or treatment of Systemic Sclerosis SSc.

Especially preferred are compounds according to formulae 3, 4 and/or 6 for use in the prevention and/or treatment of Systemic Sclerosis SSc.

Especially preferred is at least one compound according to formulae 3, 4, 6, and/or 7 in combination with vardenafil or sildenafil for use in the prevention and/or treatment of scleroderma.

A further embodiment of the invention is the combination of stimulators and/or activators of the soluble guanylate cyclase with imunosupressant therapy (i.e. cyclophosphamide CYP, methotrexate MTX,), with kinase inhibitors, (i.e. sorafenib, regorafenib, imatinib, dasatinib), with glucocorticoids (i.e. prednisolon, methylprednisoln), with Anti-CD20 antibodies, with P144 beta-glycan, with abatacept

A further embodiement of the invention is the combination of stimulators and/or activators of the soluble guanylate cyclase with ACE-inhibitors (i.e. captopril, enalapril), calcium channel blockers (i.e. nifedipine), prostanoids (i.e. iloprost), endothelin antagonists (i.e. bosentan).

Another preferred embodiment of the invention are compounds and/or combinations indicated above for use in the prevention and/or treatment of Systemic Sclerosis (SSc), diffuse Systemic Sclerosis (dSSc), limited Systemic Sclerosis (lSSc), overlap type of Systemic Sclerosis, undifferentiated type of Systemic Sclerosis, Systemic Sclerosis sine scleroderma, skin fibrosis, scleroderma, nephrogenic fibrosing dermopathy (NFD), keloid formation.

Another preferred embodiment of the invention are compounds and/or combinations indicated above for use in the prevention and/or treatment of scleroderma.

Another preferred embodiment of the invention are compounds and/or combinations indicated above for use in the prevention and/or treatment of Systemic Sclerosis SSc concomitant fibrosis of internal organs, comprising the gut, the lung, the kidney and the blood vessels.

Another preferred embodiment of the invention is the use for the production of a medicament for prevention and/or treatment of Systemic Sclerosis (SSc) comprising an effective amount of a compound and/or a combination as indicated above.

Another preferred embodiment of the invention is the use for the production of a medicament for prevention and/or treatment of scleroderma comprising an effective amount of a compound and/or a combination as indicated above.

Another preferred embodiment of the invention is the use for the production of a medicament for prevention and/or treatment of Systemic Sclerosis (SSc), diffuse Systemic Sclerosis (dSSc), limited Systemic Sclerosis (lSSc), overlap type of Systemic Sclerosis, undifferentiated type of Systemic Sclerosis, Systemic Sclerosis sine scleroderma, skin fibrosis, scleroderma, nephrogenic fibrosing dermopathy (NFD), keloid formation comprising an effective amount of a compound and/or a combination as indicated above.

Another preferred embodiment of the invention is the use for the production of a medicament for prevention and/or treatment of Systemic Sclerosis SSc concomitant fibrosis of internal organs, comprising the gut, the lung, the kidney and the blood vessels comprising an effective amount of a compound and/or a combination as indicated above.

Another preferred embodiment of the invention is the pharmaceutical formulation comprising at least one compound or one combination as indicated above for the use in the prevention and/or treatment of Systemic Sclerosis (SSc).

Another preferred embodiment of the invention is the pharmaceutical formulation comprising at least one compound or one combination as indicated above for the use in the prevention and/or

treatment of Systemic Sclerosis (SSc), diffuse Systemic Sclerosis (dSSc), limited Systemic Sclerosis (lSSc), overlap type of Systemic Sclerosis, undifferentiated type of Systemic Sclerosis, Systemic Sclerosis sine scleroderma, skin fibrosis, scleroderma, nephrogenic fibrosing dermopathy (NFD), keloid formation.

Another preferred embodiment of the invention is the pharmaceutical formulation comprising at least one compound or one combination as indicated above for the use in the prevention and/or treatment of Systemic Sclerosis (SSc).

Another preferred embodiment of the invention is the pharmaceutical formulation comprising at least one compound or one combination as indicated above for the use in the prevention and/or treatment of Systemic Sclerosis SSc concomitant fibrosis of internal organs, comprising the gut, the lung, the kidney and the blood vessels.

Another preferred embodiment of the invention is a kit comprising at least one sGC stimulator and/or activator as indicated above or a combination as indicated above for the use in the prevention and/or treatment of Systemic Sclerosis (SSc).

Another preferred embodiment of the invention is a kit as indicated above for the use in the prevention and/or treatment of Systemic Sclerosis (SSc), diffuse Systemic Sclerosis (dSSc), limited Systemic Sclerosis (lSSc), overlap type of Systemic Sclerosis, undifferentiated type of Systemic Sclerosis, Systemic Sclerosis sine scleroderma, skin fibrosis, scleroderma, nephrogenic fibrosing dermopathy (NFD), keloid formation.

Another preferred embodiment of the invention is a kit comprising at least one sGC stimulator and/or activator as indicated above or a combination as indicated above for the use in the prevention and/or treatment of scleroderma.

Another preferred embodiment of the invention is a kit as indicated above for the use in the prevention and/or treatment of Systemic Sclerosis SSc concomitant fibrosis of internal organs, comprising the gut, the lung, the kidney and the blood vessels.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral e.g., intravenous, intradermal, subcutaneous' oral (e.g.' inhalation)' transdermal (topical) transmucosal and rectal administration. Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a pharmaceutically acceptable polyol like glycerol,

propylene glycol, liquid polyetheylene glycol, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as maitol sorbitol sodium chloride in the composition.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.

Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or con1 starch; a lubricant such as magnesium stearate or sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g.' a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transderrnal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Bio degradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.

Drawings:

Figure 1: Effects of exqample 27 on mean arterial blood pressure (left) and heart rate (right).

Figure 2A and Figure 2B: Effects of example 3 on systolic blood pressure (2A) and heart rate (2B)

Figure 3A and Figure 3B: Effects of example 4 on systolic blood pressure (3A) and heart rate (3B)

Figure 4A and Figure 4B: Effects of example 7 on systolic blood pressure (4A) and heart rate (4B)

Experimental Part:

A. Examples

Abbreviations and acronyms:

aq.	aqueous solution
calc.	calculated
DCI	direct chemical ionization (in MS)
DMF	dimethylformamide
DMSO	dimethyl sulfoxide
of th.	of theory (in yield)
eq.	equivalent(s)
ESI	electrospray ionization (in MS)
Et	ethyl
fnd.	found
h	hour(s)
HPLC	high-pressure, high-performance liquid chromatography
HRMS	high-resolution mass spectrometry
conc.	concentrated
LC/MS	liquid chromatography-coupled mass spectrometry
LiHMDS	lithium hexamethyldisilazide
Me	methyl
min	minute(s)
MS	mass spectrometry

NMR	nuclear magnetic resonance spectrometry
Pd_2dba_3	tris(dibenzylideneacetone)dipalladium
Ph	phenyl
RT	room temperature
R_t	retention time (in HPLC)
THF	tetrahydrofuran
UV	ultraviolet spectrometry
v/v	volume to volume ratio (of a solution)
XPHOS	dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine

LC/MS-Methods:


Method 1: MS instrument: Waters ZQ; HPLC instrument: Agilent 1100 Series; UV DAD; Column: Thermo Hypersil GOLD 3 µ 20 mm × 4 mm; Eluent A: 1 l water + 0.5 ml 50% formic acid, Eluent B: 1 l acetonitrile + 0.5 ml of 50% formic acid; Gradient: 0.0 min 100% A → 3.0 min 10% A → 4.0 min 10% A → 4.1 min 100% A (flow rate 2.5 ml/min); Oven: 55°C; Flow rate: 2 ml/min; UV detection: 210 nm.

Method 2: Instrument: Waters ACQUITY SQD UPLC System; Column: Waters Acquity UPLC HSS T3 1.8 µ 50 × 1 mm; Eluent A: 1 l water + 0.25 ml 99% formic acid, Eluent B: 1 l acetonitrile + 0.25 ml 99% formic acid; Gradient: 0.0 min 90% A → 1.2 min 5% A → 2.0 min 5% A; Oven: 50°C; Flow rate: 0.40 ml/min; UV detection: 210 – 400 nm.

Starting compounds and intermediates:

Example 1A

2,6-Dichloro-5-fluoronicotinamide




A suspension of 25 g (130.90 mmol) of 2,6-dichloro-5-fluoro-3-cyanopyridine in conc. sulphuric acid (125 ml) was stirred at 60-65°C for 1 h. After cooling to RT, the contents of the flask were poured into ice-water and extracted three times with ethyl acetate (100 ml each time). The combined organic phases were washed with water (100 ml) and then with saturated aqueous sodium hydrogen carbonate solution (100 ml), dried and concentrated on a rotary evaporator. The material obtained was dried under a high vacuum.

Yield: 24.5 g (90% of theory)

^{1}H NMR (400 MHz, DMSO-d_6): δ = 7.95 (br s, 1H), 8.11 (br s, 1H), 8.24 (d, 1H).

Example 2A

2-Chloro-5-fluoronicotinamide



A suspension of 21.9 g (335.35 mmol) of zinc in methanol (207 ml) was admixed at RT with 44 g (210.58 mmol) of 2,6-dichloro-5-fluoronicotinamide. Then acetic acid (18.5 ml) was added and the mixture was heated with stirring at reflux for 24 h. Thereafter the contents of the flask were decanted from the zinc, and ethyl acetate (414 ml) and saturated aqueous sodium hydrogen carbonate solution (414 ml) were added, followed by intense extractive stirring. Subsequently the reaction mixture was filtered with suction over kieselguhr and the filter product was washed three times with ethyl acetate (517 ml each time). The organic phase was separated off and the aqueous phase was washed with ethyl acetate (258 ml). The combined organic phases were washed once with saturated aqueous sodium hydrogen carbonate solution (414 ml), dried and concentrated under


reduced pressure. The resulting crystals were admixed with dichloromethane (388 ml) and extractively stirred for 20 min. Filtration with suction was carried out again, and the filter product was washed with diethyl ether and sucked dry.

Yield: 20.2 g (53% of theory)

^{1}H NMR (400 MHz, DMSO-d_6): δ = 7.87 (br s, 1H), 7.99 (dd, 1H), 8.10 (br s, 1H), 8.52 (d, 1H).

Example 3A

2-Chloro-5-fluornicotinonitrile




A suspension of 46.2 g (264.66 mmol) of 2-chloro-5-fluoronicotinamide in dichloromethane (783 ml) was admixed with 81.2 ml (582.25 mmol) of triethylamine and cooled to 0°C. Then, with stirring, 41.12 ml (291.13 mmol) of trifluoroacetic anhydride were added slowly dropwise and the mixture was stirred at 0°C for 1.5 h. The reaction solution was subsequently washed twice with saturated aqueous sodium hydrogen carbon solution (391 ml each time), dried and concentrated under reduced pressure.

Yield: 42.1 g (90% of theory).

^{1}H NMR (400 MHz, DMSO-d_6): δ = 8.66 (dd, 1H), 8.82 (d, 1H).

Example 4A

5-Fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine



A suspension of 38.5 g (245.93 mmol) of 2-chloro-5-fluoronicotinonitrile was introduced in 1,2-ethanediol (380 ml) and subsequently admixed with hydrazine hydrate (119.6 ml, 2.459 mol). The mixture was heated at reflux with stirring for 4 h. On cooling, the product precipitated. The yellow crystals were admixed with water (380 ml) and subjected to extractive stirring at RT for


10 min. Then the suspension was filtered with suction over a frit, and the filter product was washed with water (200 ml) and with -10°C cold THF (200 ml). The residue was dried under a high vacuum over phosphorus pentoxide.

Yield: 22.8 g (61% of theory)

^{1}H NMR (400 MHz, DMSO-d_6): δ = 5.54 (s, 2H), 7.96 (dd, 1H), 8.38 (m, 1H), 12.07(m, 1H).

Example 5A

5-Fluoro-3-iodo-1H-pyrazolo[3,4-b]pyridine




In THF (329 ml), 10 g (65.75 mmol) of 5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine were introduced and cooled to 0°C. Then 16.65 ml (131.46 mmol) of boron trifluoride diethyl ether complex were slowly added. The reaction mixture was cooled further to -10°C. Then a solution of 10.01 g (85.45 mmol) of isopentyl nitrite in THF (24.39 ml) was added slowly, followed by stirring for a further 30 min. The mixture was diluted with cold diethyl ether (329 ml) and the resulting solid was isolated by filtration. The diazonium salt thus prepared was added in portions to a 0°C cold solution of 12.81 g (85.45 mmol) of sodium iodide in acetone (329 ml), and the mixture was stirred at RT for 30 min. The reaction mixture was poured into ice-water (1.8 l) and extracted twice with ethyl acetate (487 ml each time). The collected organic phases were washed with saturated aqueous sodium chloride solution (244 ml), dried, filtered and concentrated. This gave 12.1 g (86% purity, 60% of th.) of the desired compound in the form of a brown solid. The crude product was reacted without further purification.

LC-MS (Method 1): R_t = 1.68 min; MS (ESIpos): m/z = 264 $(M+H)^+$

Example 6A

5-Fluoro-1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine



In DMF (2538 ml), 141 g (462.11 mmol) of the compound from Example 5A were introduced and then 96.09 g (508.32 mmol) of 2-fluorobenzyl bromide and 165.62 g (508.32 mmol) of cesium carbonate were added. The mixture was stirred at RT for two hours. The reaction mixture was then poured into saturated aqueous sodium chloride solution (13 670 ml) and extracted twice with ethyl acetate (5858 ml) The collected organic phases were washed with saturated aqueous sodium chloride solution (3905 ml), dried, filtered and concentrated. The residue was chromatographed on silica gel (eluent: petroleum ether/ethyl acetate 97:3) and the product fractions were concentrated. The resulting solid was dissolved in dichloromethane and washed once with saturated aqueous sodium thiosulphate solution (500 ml) and then with saturated aqueous sodium chloride solution (500 ml). The product was concentrated to dryness and the residue was suspended with diethyl ether, isolated by filtration with suction and dried under a high vacuum. This gave 106.6 g (62% of theory) of the desired compound.


LC-MS (Method 1): R_t = 2.57 min

MS (ESIpos): m/z = 372 $(M+H)^+$

^{1}H NMR (400 MHz, DMSO-d_6): δ = 5.73 (s, 2H), 7.13 - 7.26 (m, 3H), 7.33 - 7.41 (m, 1H), 7.94 (dd, 1H), 8.69 - 8.73 (m, 1H).

Example 7A

2-[5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-nitropyrimidine-4,6-diamine




In 1,4-dioxane (86 ml), 860 mg (2.32 mmol) of the compound from Example 6A were introduced under argon and the reaction mixture was flushed with argon for 10 min. Then 3.51 ml (6.95 mmol) of hexabutylditin and 483 mg (2.55 mmol) of 2-chloro-5-nitropyrimidine-4,6-diamine (prepared by the method of *Helvetica Chimica Acta* (1951), **34**, 835-40) were added. Subsequently 860 mg (0.744 mmol) of tetrakis(triphenylphosphine)palladium(0) were added and the reaction mixture was heated at reflux overnight. It was then cooled to RT, admixed with water and extracted twice with ethyl acetate. The collected organic phases were dried over sodium sulphate, filtered and concentrated. The residue was subjected to extractive stirring in ethyl acetate, and the solid was isolated by filtration and dried under a high vacuum. This gave 355 mg (62% purity, 24% of th.) of the desired compound. The crude product was reacted without further purification.

LC-MS (Method 2): R_t = 1.03 min

MS (ESIpos): m/z = 399 $(M+H)^+$

Example 8A

5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile




A suspension of 16.03 g (43.19 mmol) of 5-fluoro-1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine (Example 6A) and 4.25 g (47.51 mmol) of copper cyanide were introduced in DMSO (120 ml) and stirred at 150°C for 2 h. After cooling, the contents of the flask were cooled to about 40°C, poured into a solution of conc. aqueous ammonia (90 ml) and water (500 ml), admixed with ethyl acetate (200 ml) and subjected to brief extractive stirring. The aqueous phase was separated off and extracted twice more with ethyl acetate (200 ml each time). The combined organic phases were washed twice with 10% strength aqueous sodium chloride solution (100 ml each time), dried and concentrated under reduced pressure. The crude product was reacted without further purification.

Yield: 11.1 g (91% of theory)

^{1}H NMR (400 MHz, DMSO-d_6): δ = 5.87 (s, 2H), 7.17 - 7.42 (m, 4H), 8.52 (dd, 1H), 8.87 (dd, 1H).

Example 9A

5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide acetate



To 2.22 g (41.07 mmol) of sodium methoxide in methanol (270 ml) were added 11.1 g (41.07 mmol) of 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile (Example 8A) and the mixture was stirred at RT for 2 h. Then 2.64 g (49.29 mmol) of ammonium chloride and acetic acid (9.17 ml) were added and the mixture was heated at reflux overnight. It was then concentrated to dryness and the residue was taken up in water (100 ml) and ethyl acetate (100 ml) and adjusted to a pH of 10 using 2N aqueous sodium hydroxide solution. It was stirred intensively at RT for about 1 h. The resulting suspension was filtered with suction and the filter product was washed with ethyl acetate (100 ml), with water (100 ml) und again with ethyl acetate (100 ml). The residue was dried under a high vacuum over phosphorus pentoxide.


Yield: 9.6 g (78% of th.)

MS (ESIpos): m/z = 288 $(M+H)^+$

^{1}H NMR (400 MHz, DMSO-d_6): δ = 1.85 (s, 3H), 5.80 (s, 2H), 7.14 - 7.25 (m, 3H), 7.36 (m, 1H), 8.42 (dd, 1H), 8.72 (dd, 1H).

Example 10A

2-[5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-[(E)-phenyldiazenyl]pyrimidine-4,6-diamine



Water (40 ml) and concentrated hydrochloric acid (7.07 ml) were admixed with stirring with 3.85 g (41.34 mmol) of aniline and this mixture was cooled to 0°C. Then a solution of 2.85 g (41.34 mmol) of sodium nitrite in water (21 ml) was added dropwise at between 0°C and 5°C, followed by stirring at 0°C for 15 min. Thereafter, at 0°C, a solution of 4.28 g (52.25 mmol) of sodium acetate in water (19 ml) was added rapidly dropwise, and then, with thorough stirring, a solution of 2.73 g (41.34 mmol) of malononitrile in ethanol (10 ml) was added dropwise. After 2 h at 0°C, the resulting precipitate was isolated by filtration with suction and washed three times with water (50 ml each time) and with petroleum ether (50 ml). The residue, still moist, was dissolved in DMF (46 ml) and added dropwise at precisely 85°C to a solution of 9.5 g (33.07 mmol) of 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-carboximidamide acetate (Example 9A) in DMF (46 ml) and triethylamine (5.76 ml). The mixture was then stirred at 100°C for 4 h and left to cool to RT overnight. The mixture was poured into water (480 ml) and subjected to extractive stirring at RT for 1 h. After the precipitate had been isolated by filtration with suction, it was washed twice with water (100 ml each time) and twice with methanol (50 ml each time) and then dried under a high vacuum.


Yield: 9.6 g (59% of theory)

LC-MS (Method 2): R_t = 1.21 min

MS (ESIpos): m/z = 458 $(M+H)^+$

Example 11A

2-[5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidine-4,5,6-triamine



Variant A: Preparation starting from Example 7A:

In pyridine (30 ml), 378 mg (0.949 mmol) of the compound from Example 7A were introduced and then 143 mg (0.135 mmol) of palladium (10% on carbon) were added. The mixture was hydrogenated overnight at RT under standard hydrogen pressure. The suspension was then filtered through kieselguhr and the filtercake was washed with ethanol. The filtrate was concentrated and yielded 233 mg (81% purity, 51% of theory) of the desired compound, which was reacted without further purification.

Variant B: Preparation starting from Example 10A:

In DMF (800 ml), 39.23 g (85.75 mmol) of the compound from Example 10A were introduced and then 4 g of palladium (10% on carbon) were added. The mixture was hydrogenated with stirring overnight under standard hydrogen pressure. The batch was filtered over kieselguhr and the filter product was washed with a little DMF and then with a little methanol, and concentrated to dryness. The residue was admixed with ethyl acetate and stirred vigorously, and the precipitate was filtered off with suction, washed with ethyl acetate and diisopropyl ether and dried under a high vacuum over Sicapent.

Yield: 31.7 g (100% of theory)


LC-MS (Method 2): R_t+ = 0.81 min

MS (ESIpos): m/z = 369 $(M+H)^+$

Working Examples:

Example 1

Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate



In pyridine (600 ml), 31.75 g (86.20 mmol) of the compound from Example 11A were introduced under argon and cooled to 0°C. Then a solution of 6.66 ml (86.20 mmol) of methyl chloroformate in dichloromethane (10 ml) was added dropwise and the mixture was stirred at 0°C for 1 h. Thereafter the reaction mixture was brought to RT, concentrated under reduced pressure and co-distilled repeatedly with toluene. The residue was stirred with water/ethanol and then filtered off on a frit, after which it was washed with ethanol and ethyl acetate. Subsequently the residue was again stirred with diethyl ether, isolated by filtration with suction and then dried under a high vacuum.

Yield: 24.24 g (65% of theory)


LC-MS (Method 2): R_t = 0.79 min

MS (ESIpos): m/z = 427 (M+H)+

^{1}H NMR (400 MHz, DMSO-d_6): δ = 3.62 (br. s, 3H), 5.79 (s, 2H), 6.22 (br. s, 4H), 7.10 - 7.19 (m, 2H), 7.19 - 7.26 (m, 1H), 7.32 - 7.40 (m, 1H), 7.67 (br. s, 0.2H), 7.99 (br. s, 0.8H), 8.66 (m, 1H), 8.89 (d, 1H).

Example 2

Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate



A quantity of 200 mg (0.469 mmol) of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate (Example 1) was introduced in THF (5 ml) at 0°C. Then 0.704 ml (0.704 mmol) of lithium hexamethyldisilazane solution (1M in THF) was added and the mixture was stirred at this temperature for 20 min. Subsequently 43.8 µl (0.704 mmol) of iodomethane were added and the mixture was warmed to RT. After 1 h at this temperature, reaction was terminated with water (1 ml) and the reaction mixture was concentrated, the residue being separated by means of preparative RP-HPLC (water (+0.05% formic acid)-acetonitrile gradient).

Yield: 90 mg (44% of theory)


LC-MS (Method 2): R_t = 0.85 min

MS (ESIpos): m/z = 441 $(M+H)^+$

^{1}H NMR (400 MHz, DMSO-d_6): δ = 3.00 (s, 3H), 3.53 (s, 2.2H), 3.66 (s, 0.8H), 5.81 (s, 2H), 6.57 (br. s, 4H), 7.13 (m, 2H), 7.22 (m, 1H), 7.35 (m, 1H), 8.67 (m, 1H), 8.87 (dd, 1H).

Example 3

Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}(2,2,2-trifluoroethyl)carbamate



A quantity of 3.470 g (8.138 mmol) of the compound from Example 1 was suspended in 35 ml of THF, admixed at 0°C with 358 mg (8.952 mmol) of sodium hydride (60% suspension in mineral oil) and stirred at 0°C for 90 min, in the course of which a solution was formed. A quantity of 2.519 g (8.952 mmol) of 2,2,2-trifluoroethyl trichloromethanesulphonate was added and the mixture was stirred at RT for 48 h. It was then stirred with water and concentrated on a rotary evaporator. The residue was taken up in ethyl acetate, and the organic phase was washed twice with water and dried over sodium sulphate. This gave 5.005 g of the target compound (79% of th., purity by HPLC 65%). A quantity of 250 mg of the residue was purified by means of preparative HPLC (Eluent: methanol/water, gradient 30:70 → 90:10).

LC-MS (Method 2): R_t = 0.97 min; MS (EIpos): m/z = 509 $[M+H]^+$.

^{1}H NMR (400 MHz, DMSO-d_6): δ [ppm] = 3.63 (s, 3H), 4.06-4.15 (m, 2H), 5.80 (s, 2H), 6.46 (s br, 4H) 7.11-7.15 (m, 2H), 7.20-7.25 (m, 1H), 7.33-7.38 (m, 1H), 8.66 (dd, 1H), 8.91 (dd, 1H).

Example A

Bleomycin-induced skin fibrosis

Local skin fibrosis was induced in 6-week-old, pathogen-free, female DBA/2 mice (Charles River, Sulzfeld, Germany) by repeated (every other day) subcutaneous injections of bleomycin (0,5 mg/ml in saline) in a defined area of the upper back. Control mice were injected in the same manner with saline only and served as reference. For all groups the injection volume was 100 µl. Concomitant to bleomycin treatment, the mice were treated orally with test drug or vehicle. Mice were treated a) with vehicle b) with 1mg/kg example 27, and c) with 3 mg/kg example 27, twice a day via gavage for 21 days. After this 3 weeks treatment period, the animals were sacrificed and skin samples were obtained for analysis.

Histological analysis

The injected skin areas were fixed in 4% formalin and embedded in paraffin. Histological sections were stained with hematoxylin and eosin for the determination of dermal thickness. The dermal thickness was determined by measuring the largest distance between the epidermal-dermal junction and the dermal-subcutaneous fat junction. The measurements were performed by an examiner blinded to the treatment of the mice.

Hydroxyproline assay

To analyze the collagen content in skin samples, hydroxyproline assay was performed. After digestion of punch biopsies (Ø 3mm) in 6M HCl for three hours at 120°C, chloramine T (0.06 M) was added and samples were mixed and incubated for 20 min at room temperature. 3.15 M perchloric acid and 20 % p-dimethylaminobenzaldehyde were added and samples were incubated for additional 20 min at 60 °C. The absorbance was determined at 557 nm.

Immunohistochemistry for α-smooth muscle actin

The expression of α-smooth muscle actin (αSMA) was analyzed in paraffin embedded sections. After deparaffinization, samples were incubated with 3% bovine serum albumin followed by incubation with 3% H_2O_2. αSMA positive cells in mouse sections were detected by incubation with monoclonal anti-αSMA antibodies (clone 1A4, Sigma-Aldrich, Steinheim, Germany). Irrelevant isotype antibodies in the same concentration were used for control (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Antibodies labeled with horseradish peroxidase (Dako, Hamburg, Germany) were used as secondary antibodies. The expression of the NICD and αSMA was visualized with DAB peroxidase substrate solution (Sigma-Aldrich). The number of myofibroblasts

was counted from 4 different sections of lesional skin for each mouse by an examiner blinded to the treatment of the mice.

		a) Bleomycin + vehicle	b) Bleomycin + 1 mg/kg example 27	c) Bleomycin + 3mg/kg example 27
Dermal thickness		1.70	1.37	1.19
Collagen content		1.31	1.19	1.11
Myofibroblast count		3.72	3.23	1.90

Table 1: **Effects of example 27 on development of Bleomycin-induced skin fibrosis.**

Fibrosis parameters expressed as x-fold change with respect to vehicle-treated control

These dose depenent and significant effects were seen with other exemples i.e. example 3, example 6 in a similar manner.

Fibrosis parameters expressed as x-fold change with respect to vehicle-treated control

	a) Bleomycin + vehicle	b) Bleomycin + 1.0 mg/kg Example 3	c) Bleomycin + 0.3 mg/kg Example 6	d) Bleomycin + 1 mg/kg Example 6	e) Bleomycin + 3 mg/kg Example 6
Dermal thickness	1.71	1.38	1.41	1.24	1.19
Collagen content	1.56	1.38	1.41	1.28	1.20
Myofibroblast count	3.86	2.55	3.13	2.05	1.49

Table 2: **Effects of example 3 and example 6 on development of Bleomycin-induced skin fibrosis**. Fibrosis parameters expressed as x-fold change with respect to vehicle-treated control

Example B

Bleomycin-induced skin fibrosis

Local skin fibrosis was induced in 6-week-old, pathogen-free, female DBA/2 mice (Charles River, Sulzfeld, Germany) by repeated (every other day) subcutaneous injections of bleomycin (0,5 mg/ml in saline) in a defined area of the upper back. Control mice were injected in the same manner with saline only. For all groups the injection volume was 100 µl. The study comprises 4 arms with

a) mice receiving saline injection for 6 weeks (serving as reference)

b) mice receiving Bleomycin injection for 6 weeks

c) mice receiving Bleomycin injection for 6 weeks and additional treatment with example 27 (3 mg/kg) twice a day via gavage for the last 3 weeks

d) mice receiving the first 3 weeks bleomycin injections and the second 3 weeks saline injection.

After 6 weeks the animals were sacrificed and skin samples were obtained for analysis.

Histological analysis, hydroxyproline assay and immunhistochemistry for α-smooth muscel actin were performed as described in the Example 1 section.

		b) Bleomycin 6 weeks	c) Bleomycin 6 weeks + 3 weeks example 27	d) Bleomycin 3 weeks + 3 weeks NaCl
Dermal thickness		1.57	1.26	1.40
Myofibroblast count		3.87	1.68	3.50

Table 3: **Effects of example 27 (3mg/kg p.o.) on established Bleomycin-induced skin fibrosis** Fibrosis parameters expressed as x-fold change with respect to vehicle-treated control (group a)

Example C

Tight skin mouse model

In addition to the mouse model of bleomycin-induced dermal fibrosis, the tight-skin (Tsk-1) mouse model of systemic sclerosis was used to evaluate the anti-fibrotic potential of test drugs.Due to a dominant mutation in fibrillin-1, the phenotype of Tsk-1 is characterized by an increased hypodermal thickness. Genotyping of Tsk-1 mice was performed by PCR with the following primers: mutated fibrillin-1/ Tsk-1 forward primer: 5' – GTTGGCAACTATACCTGCAT – 3', reverse primer: 5' – CCTTTCCTGGTAACATAGGA – 3'. Tsk-1 mice were treated daily with test drug or vehicle, respectively, by oral gavage. In addition, a group of corresponding wild type(pa/pa) mice was treated with vehicle. The treatment was started at an age of five weeks. After five weeks of treatment, mice were sacrificed by cervical dislocation and skin samples were obtained for analysis.

Histological analysis, hydroxyproline assay and immunhistochemistry for α-smooth muscel actin were performed as described in the Example 1 section.

		Tsk-1 + vehicle	Tsk-1 + 1 mg/kg example 27	Tsk-1 + 3mg/kg example 27
hypodermal thickness		5.03	3.46	2.88
Collagen content		2.46	1.61	1.67
Myofibroblast count		2.64	2.12	1.70

Table 4: **Effects of example 27 on established skin fibrosis in Tsk-mice**

Fibrosis parameters expressed as x-fold change with respect to vehicle-treated wild type mice

Example D

The haemodynamic effects of i.e. example, example 3, example 4, example 6 were analyzed in conscious mice. Telemetric implants (DSI®) were used. Signals were received with RMC1-DSI® receiver plates, compiled and analyzied with PONEMAH® physiology platform software.

The mice received either placebo (tylose), 0.3 mg/kg example 27, 1mg/kg example 27, 3mg/kg example 27 (Figure 1), 1.0 mg/kg example 3, 3.0 mg/kg example 3, 10.0 mg/kg example 3 (Figure 2A,2B), 1.0 mg/kg example 4, 3.0 mg/kg example 4, 10.0 mg/kg example 4 (figure 3A/3B), 0.3 mg/kg example 6, 1.0 mg/kg example 6, 3.0 mg/kg, 10.0 mg/kg example 6 (figure 4A/4B). The blood pressure and heart rate was monitored before and after application of placebo or the compounds. Figure 1 shows effects of example 27 on blood pressure (left) and heart rate (right), figure 2 shows the effect of example 3 on blood pressure (Figure 2A) and heart rate (Figure 2B), figure 3 shows the effects of example 4 on blood pressure (Figure 3A) and heart rate (Figure 3B), figure 4 shows the effect of example 6 on blood pressure (Figure 4A) and heart rate (figure 4B).

Example E

The effects of example 27 and vardenafil as stand alone and in combination were analyzed in vitro in human dermal fibroblasts in vitro. Example 27, vardenafil and combinations thereof significantly blocked the TGFbeta-induced Collagen gene expression and Hydroxyproline (HP) deposition.

References:

Evgenov OV, Pacher P, Schmidt PM et al. (2006): NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug. Discov. 5(9):755-68

Ferrini MG, Kovanecz I, Nolazco G (2006): Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie´s disease. B. J. U. 97:625-633.

Harris ED, et al. (2005): Kelley´s Textbook of Rhematology 7th edition. Elsevier Saunders, Philadelphia PA

Kaplan SA, Gonzalez RR (2007): Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. Rev. Urol. 9(2):73-77

Khanna D and Denton CP (2010) Evidence-based management of rapidly progressing systemic sclerosis. Best. Pract. Res. Clin. Rheumatol. 24:387-400

Knorr A, Hirth-Dietrich C, Alonso-Alija C. et al. (2008): Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung 58:71-80.

MVary K K. T. McVary, W. Monnig, J. L. Camps, Jr., J. M. Young, L. J. Tseng and G. van den Ende (2007): Sildenafil citrate improves erectile function and ur inary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J. Urol. 177: 1071-1077.

McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS. (2007): Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 177:1401-1407.

Ong VH and Denton CP (2010): Innovative therapies for systemic sclerosis Curr. Opin. Rheumatol. 22:264-272.


Porst H, Sandner P, Ulbrich E. (2008): Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr. Urol. Rep. 9:295-301.

Sandner P, Neuser D, Bischoff E (2009): Erectile dysfunction and lower urinary tract. Handb. Exp. Pharmacol. 191:507-531.


Spiera R, Gordon J, Mersten J, Magro C, Mehta M, Wildmann H, Kloiber S, Kirou K, Lyman S, Crow M (2011): Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1year, phse IIa, single-arm open-label clinical trial. Ann. Rheum. Dis. Epub Mar 11, 2011

Claims


1. Compounds according to the formulae (1) to (27)




(1)




(2)




(3)




(4)




(5)




(6)




(7)




(8)




(9)




(10)




(11)




(12)




(13)




(14)




(15)




(16)




(17)




(18)




(19)




(20)




(21)




(22)




(23)




(24)



(25)



(26)



(27)

for use in the prevention and/or treatment of Systemic Sclerosis (SSc).

2. Compounds according to formulae and (1), (2), (3), (4), (5), (6), (7) and (27) for use in the prevention and/or treatment of Systemic Sclerosis (SSc).

3. At least one compound according to claim 1 and 2 in combination with at least one PDE5 Inhibitor selected from the group of:

Tadalafil ((6R,12aR) -2,3,6,7,12,12a – Hexahydro – 2 – methyl – 6 - (3,4-methylene - dioxyphenyl) pyrazino(1',2':1,6) pyrido(3,4-b)indole-1,4-dione), *Vardenafil* (2-(2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3H-imidazo (5,1-f) (1,2,4)triazin-4-one), *Sildenafil* (3-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonyl-phenyl]-7- methy l- 9- propy l-2,4,7,8- tetrazabicyclo [4.3.0]nona -3,8,10-trien-5-one), *Udenafil* 5-[2-propyloxy-5-(1-methyl-2-pyrrolidinylethylamidosulfonyl)phenyl]-methyl-3-propyl-1,6-

dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one, *Dasantafil* 7-(3-Bromo-4-methoxybenzyl)-1-ethyl-8-[[(1,2)-2-hydroxycyclopentyl]amino]-3-(2-hydroxyethyl)-3,7-dihydro-1-purine-2,6-dione, *Avanafil* 4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide, Mirodenafil, Lodenafil, UK 369.003, UK 371.800, *SLx 2101* of Surface Logix, *LAS 34179*Triazolo[1,2-]xanthine,6-methyl-4-propyl-2-[2-propoxy-5-(4-methylpiperazino)sulfonyl]phenyl or salts, hydrates or hydrates of the salts

for use in the prevention and/or treatment of Systemic Sclerosis (SSc).

4. At least one compound according to claim 1 and 2 in combination with sildenafil or vardenafil for use in the prevention and/or treatment of Systemic Sclerosis (SSc).

5. Compounds according to claim 1 to 4 for use in the prevention and/or treatment of Systemic Sclerosis (SSc), diffuse Systemic Sclerosis (dSSc), limited Systemic Sclerosis (lSSc), overlap type of Systemic Sclerosis, undifferentiated type of Systemic Sclerosis, Systemic Sclerosis sine scleroderma, skin fibrosis, scleroderma, nephrogenic fibrosing dermopathy (NFD), nephrogenic systemic fibrosis (NSF), keloid formation.

6. Compounds according to claim 1 to 4 for use in the prevention and/or treatment of Systemic Sclerosis SSc concomitant fibrosis of internal organs, comprising the gut, the lung, the kidney and the blood vessels.

7. Compounds according to formulae 3, 4, 6, and/or 7 for use in the prevention and/or treatment of Systemic Sclerosis SSc.

8. At least one compound according to formulae 3, 4, 6, and/or 7 in combination with vardenafil or sildenafil for use in the prevention and/or treatment of Systemic Sclerosis SSc.

9. Use for the production of a medicament for prevention and/or treatment of Systemic Sclerosis (SSc) comprising an effective amount of a compound according to claim 1 to 4.

10. Use for the production of a medicament for prevention and/or treatment of Systemic Systemic Sclerosis (SSc), diffuse Systemic Sclerosis (dSSc), limited Systemic Sclerosis (lSSc), overlap type of Systemic Sclerosis, undifferentiated type of Systemic Sclerosis, Systemic Sclerosis sine scleroderma, skin fibrosis, scleroderma, nephrogenic fibrosing dermopathy (NFD), keloid formation comprising an effective amount of a compound according to 1 to 4.

11. Use for the production of a medicament for prevention and/or treatment of Systemic Sclerosis SSc concomitant fibrosis of internal organs, comprising the gut, the lung, the kidney and the blood vessels comprising an effective amount of a compound according to 1 to 4.

12. Pharmaceutical formulation comprising at least one compound or one combination according to claims 1 to 4 for the use in the prevention and/or treatment of Systemic Sclerosis (SSc).

13. Pharmaceutical formulation comprising at least one compound or one combination according to claims 1 to 4 for the use in the prevention and/or treatment of Systemic Sclerosis (SSc), diffuse Systemic Sclerosis (dSSc), limited Systemic Sclerosis (lSSc), overlap type of Systemic Sclerosis, undifferentiated type of Systemic Sclerosis, Systemic Sclerosis sine scleroderma, skin fibrosis, scleroderma, nephrogenic fibrosing dermopathy (NFD), keloid formation.

14. Pharmaceutical formulation comprising at least one compound or one combination according to claims 1 to 4 for the use in the prevention and/or treatment of Systemic Sclerosis SSc concomitant fibrosis of internal organs, comprising the gut, the lung, the kidney and the blood vessels.


15. Kit comprising at least one sGC stimulator and/or activator according to claims 1 to 2 or a combination according to claims 3 to 4 for the use in the prevention and/or treatment of Systemic Sclerosis (SSc).

16. Kit according to claim 13 for the use in the prevention and/or treatment of Systemic Sclerosis (SSc), diffuse Systemic Sclerosis (dSSc), limited Systemic Sclerosis (lSSc), overlap type of Systemic Sclerosis, undifferentiated type of Systemic Sclerosis, Systemic Sclerosis sine scleroderma, skin fibrosis, scleroderma, nephrogenic fibrosing dermopathy (NFD), keloid formation.

17. Kit according to claims 13 and 14 for the use in the prevention and/or treatment of Systemic Sclerosis SSc concomitant fibrosis of internal organs, comprising the gut, the lung, the kidney and the blood vessels.


BHC 10 1 013-Foreign Countries

Figure 1




BHC 10 1 013-Foreign Countries

Figure 1A




BHC 10 1 013-Foreign Countries

Figure 1A-1




BHC 10 1 013-Foreign Countries

Figure A-2



BHC 10 1 013-Foreign Countries

Figure 1A-3






BHC 10 1 013-Foreign Countries
Heart Rate
HR(%deviation)
30
20
10
0
-10
-20
-30
-2
0
2
4
6
8
10
12
14
16
18
20
22
24
(hours)
Example 27 0.3 mg/kg
Example 27 1 mg/kg
Example 27 3 mg/kg
0.5% Tylose 10 ml/kg

Figure 1B


BHC 10 1 013-Foreign Countries

Figure 1B-1



BHC 10 1 013-Foreign Countries

Figure 1B-2



BHC 10 1 013-Foreign Countries

Figure 1B-3




Figure 2A




BHC 10 1 013-Foreign Countries
example #3 1.0 mg/kg [n=12]
example #3 3.0 mg/kg [n=10]
example #3 10.0 mg/kg [n=6]
Untreated Control [n=6]
Vehicle Control [n=6]
Systolic Blood Pressure [mmHg] Example 3
BPsys [mmHg]
150
140
130
120
110
100
90
-60
application 9 a.m.
60
120
180
240
300
360
420
light off 480
540
600
660
720
TIME [min]

Figure 2A-1


BHC 10 1 013-Foreign Countries
Systolic Blood Pressure [mmHg] Example 3
example #3 1.0 mg/kg [n=12]
Untreated Control [n=6]
Vehicle Control [n=6]
BPsys [mmHg]
150
140
130
120
110
100
90
TIME [min]
-60
application 9 a.m.
60
120
180
240
300
360
420
light off 480
540
600
660
720

BHC 10 1 013-Foreign Countries

Figure 2A-2





Figure 2A-3


BHC 10 1 013-Foreign Countries
Systolic Blood Pressure [mmHg] Example 3
example #3 10.0 mg/kg [n=6]
Untreated Control [n=6]
Vehicle Control [n=6]
BPsys [mmHg]
TIME [min]
application 9 a.m.
light off
150
140
130
120
110
100
90
-60
60
120
180
240
300
360
420
480
540
600
660
720



BHC 10 1 013-Foreign Countries
example #3 1.0 mg/kg [n=12]
example #3 3.0 mg/kg [n=10]
example #3 10.0 mg/kg [n=6]
Vehicle Control [n=6]
Untreated Control [n=6]
Heart Rate [bpm] Example 3
HR [bpm]
750
700
650
600
550
500
450
400
350
TIME [min]
60
120
180
240
300
360
420
480
540
600
660
720
application 9 a.m.
light off

Figure 2B

Figure 2B-1



BHC 10 1 013-Foreign Countries
example #3 1.0 mg/kg [n=12]
Vehicle Control [n=6]
Untreated Control [n=6]
Heart Rate [bpm] Example 3
HR [bpm]
TIME [min]
application 9 a.m.
light off
750
700
650
600
550
500
450
400
350
-60
60
120
180
240
300
360
420
480
540
600
660
720

Figure 2B-2



BHC 10 1 013-Foreign Countries
example #3 3.0 mg/kg [n=10]
Vehicle Control [n=6]
Untreated Control [n=6]
Heart Rate [bpm] Example 3
HR [bpm]
750
700
650
600
550
500
450
400
350
-60
application
9 a.m.
60
120
180
240
300
360
420
light off
480
540
600
660
720
TIME [min]

Figure 2B-3



BHC 10 1 013-Foreign Countries
example #3 10.0 mg/kg [n=6]
Vehicle Control [n=6]
Untreated Control [n=6]
Heart Rate [bpm] Example 3
HR [bpm]
750
700
650
600
550
500
450
400
350
application 9 a.m.
-60
60
120
180
240
300
360
420
480
light off
540
600
660
720
TIME [min]

Figure 3A



BHC 10 1 013-Foreign Countries
example #4 1.0mg/kg po [n=12]
example #4 3.0mg/kg po [n=12]
example #4 10.0mg/kg po [n=6]
Vehicle Control [n=6]
Untreated Control [n=6]
Systolic Blood Pressure [mmHg] Example 4
BPsys [mmHg]
150
140
130
120
110
100
90
-60
application
9 a.m.
60
120
180
240
300
360
420
light off
480
540
600
660
720
TIME [min]

Figure 3A-1



BHC 10 1 013-Foreign Countries
Systolic Blood Pressure [mmHg] Example 4
example #4 1.0mg/kg po [n=12]
Vehicle Control [n=6]
Untreated Control [n=6]
BPsys [mmHg]
150
140
130
120
110
100
90
application 9 a.m.
60
120
180
240
300
360
420
light off 480
540
600
660
720
TIME [min]

Figure 3A-2



BHC 10 1 013-Foreign Countries
Systolic Blood Pressure [mmHg] Example 4
example #4 3.0mg/kg po [n=12]
Vehicle Control [n=6]
Untreated Control [n=6]
BPsys [mmHg]
150
140
130
120
110
100
90
-60
application 9 a.m.
60
120
180
240
300
360
420
light off 480
540
600
660
720
TIME [min]

Figure 3A-3



BHC 10 1 013-Foreign Countries
Systolic Blood Pressure [mmHg] Example 4
example #4 10.0mg/kg po [n=6]
Vehicle Control [n=6]
Untreated Control [n=6]
BPsys [mmHg]
150
140
130
120
110
100
90
-60
application
9 a.m.
60
120
180
240
300
360
420
light off
480
540
600
660
720
TIME [min]

Figure 3B



BHC 10 1 013-Foreign Countries
Heart Rate [bpm] Example 4
example #4 1.0mg/kg po [n=12]
example #4 3.0mg/kg po [n=12]
example #4 10.0mg/kg po [n=6]
Vehicle Control [n=6]
Untreated Control [n=6]
HR [bpm]
800
750
700
650
600
550
500
450
400
350
TIME [min]
-60
application 9 a.m.
60
120
180
240
300
360
420
light off
480
540
600
660
720

Figure 3B-1



BHC 10 1 013-Foreign Countries
Heart Rate [bpm] Example 4
example #4 1.0mg/kg po [n=12]
Vehicle Control [n=6]
Untreated Control [n=6]
HR [bpm]
800
750
700
650
600
550
500
450
400
350
TIME [min]
-60
application 9 a.m.
60
120
180
240
300
360
420
light off 480
540
600
660
720

Figure 3B-2



BHC 10 1 013-Foreign Countries
Heart Rate [bpm] Example 4
example #4 3.0mg/kg po [n=12]
Vehicle Control [n=6]
Untreated Control [n=6]
HR [bpm]
TIME [min]
application 9 a.m.
light off
800
750
700
650
600
550
500
450
400
350
-60
60
120
180
240
300
360
420
480
540
600
660
720

Figure 3B-3



BHC 10 1 013-Foreign Countries
Heart Rate [bpm] Example 4
example #4 10.0mg/kg po [n=6]
Vehicle Control [n=6]
Untreated Control [n=6]
HR [bpm]
TIME [min]
application 9 a.m.
light off

Figure 4A



BHC 10 1 013-Foreign Countries
-Systolic Blood Pressure [mmHg]-Example 6
example #6 0,3 mg/kg po [n=6]
example #6 1.0 mg/kg [n=15]
example #6 3.0 mg/kg [n=14]
example #6 10.0 mg/kg [n=6]
Vehicle Control [n=6]
Untreated Control [n=6]
BPsys [mmHg]
TIME [min]
application (9 a.m.)
light off

Figure 4A-1



BHC 10 1 013-Foreign Countries
Systolic Blood Pressure [mmHg] Example 6
example #6 0,3 mg/kg po [n=6]
Vehicle Control [n=6]
Untreated Control [n=6]
BPsys [mmHg]
150
140
130
120
110
100
90
-60
application (9 a.m.)
60
120
180
240
300
360
420
light off 480
540
600
660
720
TIME [min]

Figure 4A-2



BHC 10 1 013-Foreign Countries
example #6 1.0 mg/kg [n=15]
Vehicle Control [n=6]
Untreated Control [n=6]
Systolic Blood Pressure [mmHg] Example 6
BPsys [mmHg]
150
140
130
120
110
100
90
-60
application (9 a.m.)
60
120
180
240
300
360
420
light off 480
540
600
660
720
TIME [min]

Figure 4A-3



BHC 10 1 013-Foreign Countries
Systolic Blood Pressure [mmHg] Example 6
example #6 3.0 mg/kg [n=14]
Vehicle Control [n=6]
Untreated Control [n=6]
BPsys [mmHg]
150
140
130
120
110
100
90
-60
application (9 a.m.)
60
120
180
240
300
360
420
light off
480
540
600
660
720
TIME [min]

Figure 4A-4



BHC 10 1 013-Foreign Countries
Systolic Blood Pressure [mmHg] Example 6
example #6 10.0 mg/kg [n=6]
Vehicle Control [n=6]
Untreated Control [n=6]
BPsys [mmHg]
150
140
130
120
110
100
90
-60
application (9 a.m.)
60
120
180
240
300
360
420
light off
480
540
600
660
720
TIME [min]

Figure 4B



BHC 10 1 013-Foreign Countries
Heart Rate [bpm] Example 6
example #60,3 mg/kg po [n=6]
example #61.0 mg/kg [n=15]
example #63.0 mg/kg [n=14]
example #610.0 mg/kg [n=6]
Vehicle Control [n=6]
Untreated Control [n=6]
HR [bpm]
750
700
650
600
550
500
450
400
350
-60
application (9 a.m.)
60
120
180
240
300
360
420
light off
480
540
600
660
720
TIME [min]

Figure 4B-1



BHC 10 1 013-Foreign Countries
example #6 0,3 mg/kg po [n=6]
Vehicle Control [n=6]
Untreated Control [n=6]
Heart Rate [bpm] Example 6
HR [bpm]
750
700
650
600
550
500
450
400
350
TIME [min]
-60
application (9 a.m.)
60
120
180
240
300
360
420
light off
480
540
600
660
720

Figure 4B-2



BHC 10 1 013-Foreign Countries
Heart Rate [bpm] Example 6
example #6 1.0 mg/kg [n=15]
Vehicle Control [n=6]
Untreated Control [n=6]
HR [bpm]
TIME [min]
application (9 a.m.)
light off
750
700
650
600
550
500
450
400
350
-60
60
120
180
240
300
360
420
480
540
600
660
720

Figure 4B-3




BHC 10 1 013-Foreign Countries
Heart Rate [bpm] Example 6
example #6 3.0 mg/kg [n=14]
Vehicle Control [n=6]
Untreated Control [n=6]
HR [bpm]
750
700
650
600
550
500
450
400
350
TIME [min]
-60
application (9 a.m.)
60
120
180
240
300
360
420
light off
480
540
600
660
720

Figure 4B-4


BHC 10 1 013-Foreign Countries
Heart Rate [bpm] Example 6
example #6 10.0 mg/kg [n=6]
Vehicle Control [n=6]
Untreated Control [n=6]
HR [bpm]
750
700
650
600
550
500
450
400
350
application (9 a.m.)
60
120
180
240
300
360
420
light off
480
540
600
660
720
TIME [min]

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2011/058433

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D471/04 A61K31/437
ADD. A61P9/00 A61P15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 03/095451 A1 (BAYER AG [DE]; ALONSO-ALIJA CRISTINA [DE]; BISCHOFF ERWIN [DE]; MUENTE) 20 November 2003 (2003-11-20) cited in the application Formel I,; page 14, lines 4-24; claims 1,6,10-13; examples 5,8	1-17
A	WO 98/16223 A1 (BAYER AG [DE]; ROBYR CHANTAL [DE]; STRAUB ALEXANDER [DE]; NIEWOEHNER U) 23 April 1998 (1998-04-23) Formel I,; page 9, line 19 - page 10, line 2; claims 1,7-9; example 13	1-17

-/--

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
7 October 2011	21/10/2011

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Rudolf, Manfred

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2011/058433

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00/06569 A1 (BAYER AG [DE]; STRAUB ALEXANDER [DE]; FEURER ACHIM [DE]; ALONSO ALIJA) 10 February 2000 (2000-02-10) Formel I,; page 53, line 24 - page 54, line 11; claims 1,11-15 page 32 - page 33	1-17
A	DE 199 43 635 A1 (BAYER AG [DE]) 15 March 2001 (2001-03-15) claim 1; example 8	1-17
A	WO 2010/031791 A1 (BIOVITRUM AB PUBL [SE]; SAVORY EDWARD [GB]; SIMPSON IAIN [GB]) 25 March 2010 (2010-03-25) Formula I; page 8, lines 8-22; claims 8,11,14	1-17
A	US 2009/286782 A1 (IBRAHIM PRABHA N [US] ET AL) 19 November 2009 (2009-11-19) Formula I; paragraphs [0208], [0210]; claims 14,15,17,18	1-17
A	WO 02/067851 A2 (ALTEON INC [US]) 6 September 2002 (2002-09-06) page 8, lines 8-19	1-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2011/058433

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03095451 A1	20-11-2003	AR 039789 A1	02-03-2005
		AT 330957 T	15-07-2006
		AU 2003233061 A1	11-11-2003
		BR 0309855 A	01-03-2005
		CA 2485143 A1	20-11-2003
		CN 1665811 A	07-09-2005
		DE 10220570 A1	20-11-2003
		DK 1506193 T3	09-10-2006
		DO P2003000639 A	15-11-2003
		EC SP045414 A	03-01-2005
		EP 1506193 A1	16-02-2005
		ES 2268363 T3	16-03-2007
		HK 1082247 A1	14-03-2008
		HR 20041166 A2	31-08-2005
		IL 164958 A	17-05-2010
		JP 4455321 B2	21-04-2010
		JP 2005531553 A	20-10-2005
		MX PA04011003 A	14-02-2005
		NO 329105 B1	23-08-2010
		NZ 536417 A	31-08-2006
		PE 01972004 A1	22-04-2004
		PT 1506193 E	31-10-2006
		RU 2339638 C2	27-11-2008
		TW I282792 B	21-06-2007
		UA 78314 C2	15-03-2007
		US 2006052397 A1	09-03-2006
		UY 27793 A1	31-12-2003
		ZA 200408925 A	04-11-2005
WO 9816223 A1	23-04-1998	AT 311184 T	15-12-2005
		AU 733967 B2	31-05-2001
		AU 5049498 A	11-05-1998
		BR 9712304 A	31-08-1999
		CA 2268314 A1	23-04-1998
		CZ 9901292 A3	14-07-1999
		DE 19642255 A1	16-04-1998
		DE 59712501 D1	05-01-2006
		EE 9900156 A	15-12-1999
		EP 0932403 A1	04-08-1999
		ES 2252777 T3	16-05-2006
		HU 9903885 A2	28-11-2000
		ID 22162 A	09-09-1999
		IL 129318 A	14-06-2001
		JP 2001502318 A	20-02-2001
		JP 2009114205 A	28-05-2009
		NO 991685 A	09-04-1999
WO 9816223 A1		NZ 335091 A	29-09-2000
		PL 332719 A1	11-10-1999
		SK 46599 A3	14-02-2000
		TR 9900782 T2	21-07-1999
		TW 442482 B	23-06-2001
		US 6180656 B1	30-01-2001
WO 0006569 A1	10-02-2000	AT 313543 T	15-01-2006
		AU 751316 B2	15-08-2002
		AU 5284099 A	21-02-2000
		BG 105177 A	30-11-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2011/058433

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		BR 9912562 A	02-05-2001
		CA 2339071 A1	10-02-2000
		CN 1317005 A	10-10-2001
		CO 5080799 A1	25-09-2001
		DE 19834044 A1	03-02-2000
		EP 1102768 A1	30-05-2001
		ES 2255288 T3	16-06-2006
		HK 1040712 A1	20-05-2005
		HU 0103815 A2	29-07-2002
		ID 28240 A	10-05-2001
		JP 2002521483 A	16-07-2002
		NO 20010149 A	26-03-2001
		NZ 509599 A	25-07-2003
		PL 345675 A1	02-01-2002
		RU 2232161 C2	10-07-2004
		SK 1302001 A3	06-08-2001
		SV 1999000118 A	02-05-2000
		TR 200100238 T2	21-06-2001
		TW 509691 B	11-11-2002
		UA 72219 C2	17-09-2001
		US 6743798 B1	01-06-2004
		ZA 200100222 A	07-08-2001
DE 19943635 A1	15-03-2001	AR 033346 A1	17-12-2003
		AT 299134 T	15-07-2005
		AU 767750 B2	20-11-2003
		AU 7000900 A	17-04-2001
		BG 106494 A	31-03-2003
		BR 0014179 A	21-05-2002
		CA 2387107 A1	22-03-2001
		CN 1390196 A	08-01-2003
		CO 5221052 A1	28-11-2002
		CU 23105 A3	20-01-2006
		CZ 20020918 A3	11-09-2002
		DK 1216225 T3	07-11-2005
DE 19943635 A1		EE 200200130 A	15-04-2003
		WO 0119780 A2	22-03-2001
		EP 1216225 A2	26-06-2002
		ES 2244466 T3	16-12-2005
		HK 1053638 A1	08-05-2009
		HR 20020307 A2	29-02-2004
		HU 0203418 A2	28-02-2003
		IL 148134 A	26-11-2008
		JP 4456312 B2	28-04-2010
		JP 2003509401 A	11-03-2003
		JP 2010077153 A	08-04-2010
		MA 25875 A1	01-10-2003
		MX PA02002651 A	23-10-2002
		NO 20021226 A	03-05-2002
		NZ 517709 A	28-05-2004
		PE 06372001 A1	12-07-2001
		PL 353790 A1	01-12-2003
		PT 1216225 E	30-11-2005
		RU 2280025 C2	20-07-2006
		SK 3382002 A3	02-07-2002
		SV 2002000169 A	15-01-2002
		TR 200200649 T2	22-07-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2011/058433

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		TW I225045 B	11-12-2004
		US 7087644 B1	08-08-2006
		US 2006094769 A1	04-05-2006
		US 2009203906 A1	13-08-2009
		US 2010317854 A1	16-12-2010
		UY 26332 A1	30-04-2001
		ZA 200201299 A	28-05-2003
WO 2010031791 A1	25-03-2010	EP 2328895 A1	08-06-2011
		US 2011195992 A1	11-08-2011
US 2009286782 A1	19-11-2009	AR 071839 A1	21-07-2010
		WO 2009143018 A2	26-11-2009
WO 02067851 A2	06-09-2002	CA 2433425 A1	06-09-2002
		EP 1355645 A2	29-10-2003
		JP 2004525904 A	26-08-2004
		MX PA03005954 A	24-05-2004